Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Oculis Holding AG (OCS : NSDQ)

• Company Description    Oculis Holding AG is a biopharmaceutical company which develops novel topical treatments for ophthalmic diseases for both back- and front-of-the-eye. Its product candidate includes OCS-01, OCS-02 and OCS-05. Oculis Holding AG is based in Zug, Switzerland. Number of Employees: 49

• Price / Volume Information    Yesterday's Closing Price: $19.97 Daily Weekly Monthly 20 Day Moving Average: 99,197 shares Shares Outstanding: 52.38 (millions) Market Capitalization: $1,045.93 (millions) Beta: 0.31 52 Week High: $23.08 52 Week Low: $14.00 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week 1.37% 1.54% 12 Week -5.49% -7.01% Year To Date 0.00% 0.00%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL BAHNHOFSTRASSE 7 - ZUG,V8 6300 CHE ph: 41-41-711-9325 fax: - ir@oculis.com http://www.oculis.com

• General Corporate Information    Officers Riad Sherif - Chief Executive Officer Anthony Rosenberg - Chairman Sylvia Cheung - Chief Financial Officer Christina Ackermann - Director Lionel Carnot - Director Peer Information Oculis Holding AG (CORR.) Oculis Holding AG (RSPI) Oculis Holding AG (CGXP) Oculis Holding AG (BGEN) Oculis Holding AG (GTBP) Oculis Holding AG (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: H5870P102 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 09/01/25 Next Expected EPS Date: 03/10/26 Share - Related Items Shares Outstanding: 52.38 Most Recent Split Date: (:1) Beta: 0.31 Market Capitalization: $1,045.93 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.47 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-2.09 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 7.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: 4.79% Last Dividend Paid: NA - $0.00 Next EPS Report Date: 03/10/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 6.41 Price/Cash Flow: - Price / Sales: 1,112.69 EPS Growth vs. Year Ago Period: 27.27% vs. Previous Quarter: 32.20% Sales Growth vs. Year Ago Period: 21.60% vs. Previous Quarter: -3.80% ROE 12/31/25 - - 09/30/25 - -80.82 06/30/25 - -90.31 ROA 12/31/25 - - 09/30/25 - -61.18 06/30/25 - -67.85 Current Ratio 12/31/25 - - 09/30/25 - 4.47 06/30/25 - 4.55 Quick Ratio 12/31/25 - - 09/30/25 - 4.47 06/30/25 - 4.55 Operating Margin 12/31/25 - - 09/30/25 - -12,915.42 06/30/25 - -13,958.12 Net Margin 12/31/25 - - 09/30/25 - -12,915.42 06/30/25 - -13,958.12 Pre-Tax Margin 12/31/25 - - 09/30/25 - -12,947.55 06/30/25 - -13,992.32 Book Value 12/31/25 - - 09/30/25 - 3.12 06/30/25 - 3.97 Inventory Turnover 12/31/25 - - 09/30/25 - - 06/30/25 - - Debt-to-Equity 12/31/25 - - 09/30/25 - 0.02 06/30/25 - 0.01 Debt-to-Capital 12/31/25 - - 09/30/25 - 1.54 06/30/25 - 0.50

Powered by Zacks Investment Research ©